We show that, in the context of chemo-immunotherapy, IL-1β enhances anti-tumor immunity by inducing tumor-cell CXCL10 expression and recruiting CD8<sup>+</sup> T cells, thereby sensitizing "cold" tumors to treatment. Here, CD8A is linked to neoplasm.